Today news
Entest BioMedical, Inc. in Discussions to Acquire Nanotechnology Delivery System for Cancer Therapy
SAN DIEGO, CA--(Marketwired - Jun 1, 2015) - Entest BioMedical Inc. (OTC PINK: ENTB) announced today that the Company is currently in discussions to acquire a nanotechnology for the delivery of cancer therapeutics in both animals and humans.
This technology would potentially allow more potent therapeutics to be administered to patients than is currently possible. The reason this is possible is due to the fact that the nanoparticles sequester the drug and allow it to travel throughout the body with minimal toxicity, only releasing the drug directly to the tumor.
A Company spokesman stated: "We are enthusiastic about this potential acquisition. Although Entest has historically focused on veterinary biotechnology, we believe that the acquisition of this nanotechnology would enable us to pursue partnering opportunities in the human market as well as the veterinary market."
